H.C. Wainwright analyst Patrick Trucchio lowered the firm’s price target on Precision BioSciences to $3 from $5 and keeps a Buy rating on the shares after the company announced completion of a strategic transaction with Imugene Limited. The analyst views the deal as a “clear positive,” extending Precision’s cash runway through Q3 of 2025 and enabling it to focus exclusively on internal gene editing programs, but lowered the target o better reflect the value from its CAR T pipeline.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on DTIL:
- Precision BioSciences CAR T deal marks pivot to gene editing, says Stifel
- Precision BioSciences completes transaction with Imugene for azer-cel in cancer
- Precision BioSciences trading resumes
- Precision BioSciences trading halted, news pending
- Precision BioSciences reports Q2 EPS (10c), consensus (24c)